Visiting Professor, Harvard Medical School/Dana-Farber Cancer Institute President, European Research Initiative on CLL (ERIC) Treasurer, International Workshop on CLL (iwCLL) Associate Editor, CLL at Hemasphere
The Lymphoma Research Foundation convened a workshop comprising a panel of CLL/SLL experts in the United States to develop consensus recommendations for selection and sequencing of therapies for patients with CLL/SLL in the United States. Herein, the recommendations are compiled for use as a ...
Remember, supplements can’t treat cancer and don’t take the place of medical treatments. If you’re thinking about taking something, talk to your oncologist first so you can find out what’s safe and what the research shows. Show Sources Next Article Living With Treatment Side Effects If ...
[11] Smith, A., et al., Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer, 2015. 112(9): p. 1575-84.[12] Maynadie, M., et al., Splenic Marginal Zone Lymphoma: French Registries Population-Ba...
immunomodulatory and antiangiogenic properties. Lenalidomide, with or without rituximab, is recommended for refractory or relapsed CLL.[12]In a phase 2 study by the CLL Research Consortium, lenalidomide plus rituximab also demonstrated benefit in the initial treatment of CLL.[21]The regimen is as ...
Learn more about the field, the research, and the people living with cancer. Futurelab A Genentech science education program to inspire the next generation of scientists. Two Scientists Walk Into a Bar Listen to our podcast, where researchers talk about their work answering the toughest questions...
[12] Maynadie, M., et al., Splenic Marginal Zone Lymphoma: French Registries Population-Based Treatment and Survival Analyses (2002-2014). Blood, 2020. 136. [13] Leukemia & Lymphoma Society, Marginal Zone Lymphoma. Available at: https://www.lls.org/research/marginal-zone-lymphoma-mzl....
Emerging Treatment Options for Patients With CLL Clinical Thought Released: April 21, 2022 Expires: April 20, 2023 View Activity Cases in CLL: Frontline Therapy Selection and Clinical Trial Considerations for a Patient With Multiple Comorbidities Clinical Thought Released: July 07, 2022 Expires:...
Additionally, the question of whether or not treatment should be stopped for patients with extended responses will also require further study. In general, research has indicated that ibrutinib is effective across a variety of therapeutic settings in CLL, including high-risk patients with 17p ...
In particular when those patients have an unmutated IGHV gene, they tend to progress very rapidly and probably 50% to 75% need treatment within 1 year of diagnosis. The good news as you alluded to is that this abnormality is not that common at diagnosis, it probably makes up only about ...